XBI vs XLV
SPDR S&P Biotech ETF vs Health Care Select Sector SPDR Fund
- • XLV has the lower expense ratio at 0.08% vs 0.35% for XBI.
- • XLV pays a higher dividend yield (1.38%).
Side-by-side metrics
| Metric | XBI | XLV |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.08% |
Dividend yield Trailing 12-month yield. | 0.35% | 1.38% |
AUM Assets under management — bigger funds are typically more liquid. | $10.92B | $49.10B |
YTD return | 28.80% | 23.16% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.01 | 0.41 |
P/E ratio | — | 30.63 |
Last price | $156.41 | $187.94 |
Inception | — | — |
Issuer | State Street | State Street |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
XLV top holdings
| LLY | Eli Lilly and Co | 16.88% |
| JNJ | Johnson & Johnson | 9.80% |
| ABBV | AbbVie Inc | 7.76% |
| MRK | Merck & Co Inc | 5.49% |
| UNH | UnitedHealth Group Inc | 5.44% |
| TMO | Thermo Fisher Scientific Inc | 3.84% |
| AMGN | Amgen Inc | 3.75% |
| GILD | Gilead Sciences Inc | 3.15% |
| ABT | Abbott Laboratories | 2.74% |
| PFE | Pfizer Inc | 2.59% |
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.
About XLV
XLV (Health Care Select Sector SPDR Fund) is S&P 500 health care sector. Managed by State Street, the fund carries $49.1B in assets under management, an expense ratio of 0.08%, a dividend yield of 1.38%. Its largest holding is Eli Lilly and Co (LLY), which represents 16.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.